← Back to headlines
Gilead Sciences Outlook Cut Sharply on IPR&D and Financing Costs
Gilead Sciences, Inc. (GILD) has seen its outlook cut sharply due to significant $11.5 billion IPR&D (In-Process Research and Development) and financing costs, impacting its financial projections.
11 May, 20:01 — 11 May, 20:01
Sources
Showing 1 of 1 sources
Related Stories
Lionel Richie Hospitalized in ICU After Collapsing During St. Louis Concert
19m ago
Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue
1h ago
Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases
3h ago
England Pharmacies to Offer Free Quick Cholesterol Screening Tests
11h ago